Ticagrelor + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease
Trial Timeline
Jul 9, 2015 → Nov 16, 2016
NCT ID
NCT02482298About Ticagrelor + Placebo
Ticagrelor + Placebo is a phase 2 stage product being developed by AstraZeneca for Sickle Cell Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02482298. Target conditions include Sickle Cell Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03615924 | Phase 3 | Terminated |
| NCT03354429 | Phase 3 | Completed |
| NCT02482298 | Phase 2 | Completed |
| NCT02352402 | Phase 3 | UNKNOWN |
| NCT02110303 | Phase 2/3 | Completed |
| NCT02335099 | Phase 1/2 | Completed |
| NCT01998399 | Phase 2 | Terminated |
| NCT02070653 | Phase 2 | Completed |
| NCT01347580 | Approved | Completed |
Competing Products
20 competing products in Sickle Cell Disease